Table 3.
Vaccine Candidates for Protection Against COVID‐19
| Vaccine | Developer | Type | Trial Phase/Included Participants | Efficacy | Distribution | EUA |
|---|---|---|---|---|---|---|
| BNTv162b2 154 | Pfizer‐BioNTech | mRNA | Completed/ 43 548 participants aged ≥16 y | 52% after the first dose, 95% after the second dose | Freezing temperatures | Yes |
| mRNA‐1273 155 | Moderna | mRNA | Completed/ 30 420 participants aged ≥18 y | 94.1% after the second dose | 2‐8°C for >30 days | Yes |
| AZD1222 156 | AstraZeneka and Oxford university | Replication‐deficient viral vector | Phase 3/ 11 636 participants aged ≥18 y | 70.4% after the second dose | 2‐8°C | Expected |
| CoronaVac 157 | Sinovac | Inactivated virus | Phase 1/2 participants aged 18‐59 years | Unknown | 2‐8°C | Not yet applied |
| Sinopharm 157 | Sinopharm | Inactivated virus | Phase 1/2 participants aged 18‐59 years | Unknown | 2‐8°C | Not yet applied |
| Ad26.COV2.S 158 | Johnson & Johnson | Replication‐deficient viral vector | Phase 1/2 participants aged 18‐55 or ≥65 y | Unknown | 2‐8°C | Not yet applied |
| rAd26 and rAd5159 | Sputnik V | Recombinant viral vectors | Phase 1/2 participants aged 18‐60 y | Unknown | 2‐8°C for lyophilized form | Not yet applied |
| NVX‐CoV2373 160 | Novavax | Protein subunit | Phase 1/2 participants aged 18‐59 y | Unknown | 2‐8°C | Not yet applied |
EUA, emergency use authorization; mRNA, messenger ribonucleic acid.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.